Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Study product A (Wonderlab wonder4shape)
Chongqing Precision Biotech Co., Ltd
Overweight and Obesity
1 trial -
Study product A (Wonderlab wonder4shape)
Chongqing Precision Biotech Co., Ltd
Overweight
1 trial -
Suanzaoren Decoction and Huanglian Wendan Decoction
The First People's Hospital of Lianyungang
Traditional Chinese Medicine
1 trial -
Subconjunctival dexamethasone and general anesthesia
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cataract
1 trial -
Super Cereal Plus (SC+)
United Therapeutics Europe Ltd
Moderate Acute Malnutrition (MAM)
1 trial -
Supplementary Food
United Therapeutics Europe Ltd
Moderate Acute Malnutrition
1 trial -
Surgery combined with Target-reduction intensity-modulated radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Surgery-radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma
1 trial -
TNK plus standard medical treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Ischemic Stroke
1 trial -
TPO-RA
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Primary Immune Thrombocytopenic Purpura
1 trial -
Tacrolimus+Mycophenolate mofetil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lupus Nephritis
1 trial -
Tadalafil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pulmonary Arterial Hypertension (PAH)
1 trial -
Tafolecimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Coronary Syndrome
1 trial -
Tamsulosin Hydrochloride
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Benign Prostatic Hyperplasia
1 trial -
Technochrom C1-INH Kit
Takeda
Hereditary Angioedema (HAE)
1 trial -
Telmisartan
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypertension
1 trial -
Terlipressin treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Septic Shock
1 trial -
Thalidomide
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses
Sinovac Research and Development Co.,
Poliomyelitis
1 trial -
Ticagrelor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Brain Disease
1 trial -
Tirzepatide
United Therapeutics Europe Ltd
Hypertension
1 trial -
Tislelizumab combined with Lenvatinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Initially Unresectable Hepatocellular Carcinoma
1 trial -
Tolcapone
BRIGHT MINDS BIOSCIENCES INC.
Nicotine Dependence
1 trial -
Topical compound tripterygium
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Active Rheumatoid Arthritis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources